Irvine, California, USA, August 7, 2026
Tarsus Pharmaceuticals has announced a definitive agreement to acquire Alkeus Pharmaceuticals, a privately held biotechnology company focused on retinal diseases, in a strategic move that significantly strengthens its position in eye care innovation. The acquisition adds gildeuretinol (ALK-001), a Phase III investigational oral therapy for Stargardt disease, to the company’s expanding ophthalmology pipeline. The transaction supports Tarsus’ long-term strategy of building a comprehensive eye care portfolio by targeting diseases with significant unmet medical needs. Stargardt disease, one of the most common inherited retinal disorders, currently has no FDA-approved treatment, making ALK-001 a potentially transformative therapy. The investigational medicine has already been evaluated in more than 400 patients, demonstrating encouraging structural, functional, and long-term tolerability findings over more than seven years of clinical evaluation. In addition, the therapy has received Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations from the U.S. FDA, highlighting its potential importance in treating a serious rare disease.
Acquisition Strengthens Retina Pipeline and Rare Disease Portfolio
The acquisition represents another major milestone in Tarsus Pharmaceuticals’ expansion into retinal diseases following its earlier investment in ophthalmic innovation. The addition of gildeuretinol (ALK-001) complements the company’s growing retina portfolio and broadens its presence beyond existing eye care programs. ALK-001 is a once-daily oral investigational therapy specifically designed to reduce the formation of toxic vitamin A dimers, which contribute to retinal degeneration in patients with Stargardt disease while preserving the normal visual cycle. The therapy targets the underlying biology of the disease rather than simply managing symptoms, offering a novel therapeutic approach for patients who currently have limited treatment options. Top-line data from the ongoing Phase III NORTHSTAR trial are expected during the second half of 2029, with the study evaluating approximately 230 patients using retinal lesion growth and low-light visual acuity as primary clinical endpoints.
Clinical Data Demonstrate Encouraging Long-Term Progress
Clinical development of ALK-001 has generated encouraging evidence supporting continued late-stage evaluation. Across multiple studies involving more than 400 treated individuals, investigators reported meaningful structural and functional improvements together with an extensive long-term safety profile. In one study, patients receiving ALK-001 demonstrated a 29.5% slower annualized growth rate of retinal atrophic lesions compared with untreated controls. Additional findings showed that treated patients were 87% less likely to experience significant low-light visual acuity loss than placebo-treated participants. Importantly, investigators reported no treatment-related effects on night vision, dark adaptation, or color vision, an important consideration for a therapy expected to be administered chronically. These clinical findings formed the scientific basis for the ongoing Phase III NORTHSTAR trial, which has been designed in collaboration with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Advertisement
Strategic Acquisition Supports Future Eye Care Innovation
The proposed acquisition further strengthens Tarsus Pharmaceuticals’ long-term vision of becoming a leader in ophthalmology, combining commercial capabilities with a growing pipeline of innovative therapies addressing serious eye diseases. Under the transaction terms, Tarsus will provide approximately $450 million in upfront consideration, consisting of cash and common stock, with additional milestone payments tied to potential regulatory approval and commercial launch. The transaction has already been approved by the boards of both companies and is expected to close during 2026, subject to customary regulatory conditions. By integrating ALK-001 alongside existing investigational programs such as IRX-101, Tarsus is expanding its ability to address both common and rare ophthalmic disorders. If successfully developed and approved, gildeuretinol could become the first FDA-approved therapy for Stargardt disease, offering a significant advancement for patients affected by this progressive inherited retinal disorder while reinforcing Tarsus’ leadership in next-generation eye care therapeutics.
Source: Tarsus Pharmaceuticals, Alkeus Pharmaceuticals press release
